Nanoparticulate carriers: an emerging tool for breast cancer therapy

References

• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137–50
   PubMed Web of Science ®Google Scholar
• Kawase T, Matsuo K, Suzuki T, et al. FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: results of a case control study in Japan. Int J Cancer 2009;125:1946–52
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. Int J Cancer 2001;94:153–6
   PubMed Web of Science ®Google Scholar
• Rakha EA, El-Sayed ME, Reis-Filho JS, Ellis IO. Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology 2008;52:67–81
   PubMed Web of Science ®Google Scholar
• Masood S. The current status of breast cancer among resource-limited countries. Middle East J Cancer 2010;1:1–4
   Google Scholar
• Dunning AM, Healey CS, Pharoah PD, et al. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:843–54
   PubMed Web of Science ®Google Scholar
• Zhenwu FMS. The most prevalent cancer of the women breast in the city of Taiz. Acad J Cancer Res 2011;4:5–9
   Google Scholar
• Santarosa M, Dolcetti R, Magri MD, et al. BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy. Int J Cancer 1999;83:5–9
   PubMed Web of Science ®Google Scholar
• Clavel-Chapelon F, Launoy G, Auquier A, et al. Reproductive factors and breast cancer risk: effect of age at diagnosis. Ann Epidemiol 1995;5:315–20
   PubMedGoogle Scholar
• Ursin G, Bernstein L, Lord SJ, et al. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br J Cancer 2005;93:364–71
   PubMed Web of Science ®Google Scholar
• Grodzinski P, Silver M, Molnar LK. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn 2006;6:307–18
   PubMed Web of Science ®Google Scholar
• Om Pal Singh, Nehru RM. Nanotechnology and cancer treatment. Asian J Exp Sci 2008;22:245–50
   Google Scholar
• Bertucci F, Birnbaum D. Reasons for breast cancer heterogeneity. J Biol 2008;7:6
   PubMedGoogle Scholar
• Bertucci F, Viens P, Hingamp P, et al. Breast cancer revisited using DNA array-based gene expression profiling. Int J Cancer 2003;103:565–71
   PubMed Web of Science ®Google Scholar
• Harichand-Herdt S, O'regan RM. Identifying subsets of metastatic breast cancer patients likely to benefit from treatment with the epothilone B analog ixabepilone. Am J Clin Oncol 2010;33:561–7
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Neo S-Y, Mcshane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci 2003;100:10393–8
   PubMed Web of Science ®Google Scholar
• Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest 2011;121:3797–803
   PubMed Web of Science ®Google Scholar
• Su Y, Zheng Y, Zheng W, et al. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer 2011;11:292
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747–52
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah S, Chin S, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346–52
   Google Scholar
• Abaan OD, Criss S, Wayne E. Gene therapy in human breast cancer. Turk J Med Sci 2002;32:283–91
   Google Scholar
• De Britto AJ, RaDaC TLS. Prediction of biological activity spectra for few anticancer drugs derived from plant sources. Ethnobot Leaflets 2001;12:801–10
   Google Scholar
• Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 2006;5:1909–17
   PubMed Web of Science ®Google Scholar
• Lee PY, Wong KK. Nanomedicine: a new frontier in cancer therapeutics. Curr Drug Deliv 2011;8:245–53
   PubMed Web of Science ®Google Scholar
• Seigneuric R, Markey L, Nuyten DS, et al. From nanotechnology to nanomedicine: applications to cancer research. Curr Mol Med 2010;10:640–52
   PubMed Web of Science ®Google Scholar
• Pridgen EM, Langer R, Farokhzad OC. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine (London) 2007;2:669–80
   PubMed Web of Science ®Google Scholar
• Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today 2010;15:842–50
   PubMed Web of Science ®Google Scholar
• Cuenca AG, Jiang H, Hochwald SN, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346–52
   PubMed Web of Science ®Google Scholar
• Gao X, Cui Y, Levenson RM, et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22:969–76
   PubMed Web of Science ®Google Scholar
• Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003;3:319–28
   PubMed Web of Science ®Google Scholar
• Kim KY. Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomedicine 2007;3:103–10
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2011;2:281–98
   PubMed Web of Science ®Google Scholar
• Chari RVJ. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv Drug Deliv Rev 1998;31:89–104
   PubMed Web of Science ®Google Scholar
• Tanaka T, Decuzzi P, Cristofanilli M, et al. Nanotechnology for breast cancer therapy. Biomed Microdevices 2009;11:49–63
   PubMed Web of Science ®Google Scholar
• Bharali DJ, Khalil M, Gurbuz M, et al. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomed 2009;4:1–7
   PubMed Web of Science ®Google Scholar
• Service RF. Nanotechnology: nanoparticle Trojan horses gallop from the lab into the clinic. Science 2010;330:314–15
   PubMed Web of Science ®Google Scholar
• Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res 2010;62:90–9
   PubMed Web of Science ®Google Scholar
• Kateb B, Chiu K, Black KL, et al. Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy? NeuroImage 2011;54:S106–24
   PubMed Web of Science ®Google Scholar
• Betty YSK, Rutka JT, Warren CWC. Nanomedicine. N Engl J Med 2010;363:2434–43
   PubMed Web of Science ®Google Scholar
• Michael LE, Stephen AC, Arthur GE, et al. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomed: Nanotechnol Biol Med 2013;9:11–14
   Google Scholar
• Davis FF. The origin of pegnology. Adv Drug Deliv Rev 2002;54:457–8
   PubMed Web of Science ®Google Scholar
• De Jong WH, Borm PJ. Drug delivery and nanoparticles:applications and hazards. Int J Nanomed 2008;3:133–49
   PubMed Web of Science ®Google Scholar
• Ehdaie B. Application of nanotechnology in cancer research: review of progress in the National Cancer Institute's Alliance for Nanotechnology. Int J Biol Sci 2007;3:108–10
   PubMed Web of Science ®Google Scholar
• Gindy ME, Prud'homme RK. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv 2009;6:865–78
   PubMed Web of Science ®Google Scholar
• Grzelczak M, Vermant J, Furst EM, et al. Directed self-assembly of nanoparticles. ACS Nano 2010;4:3591–605
   PubMed Web of Science ®Google Scholar
• Prabhu VU, Siddik G, Berlin VM, Guruvayoorappan C. Nanoparticles in drug delivery and cancer therapy: the giant rats tail. J Cancer Ther 2011;2:325–34
   Google Scholar
• Carpin LB, Bickford LR, Agollah G, et al. Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells. Breast Cancer Res Treat 2011;125:27–34
   PubMed Web of Science ®Google Scholar
• Marches R, Mikoryak C, Wang R-H, et al. The importance of cellular internalization of antibody-targeted carbon nanotubes in the photothermal ablation of breast cancer cells. Nanotechnology 2011;22:095101
   PubMed Web of Science ®Google Scholar
• Wu X, Liu H, Liu J, et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 2003;21:41–6
   PubMed Web of Science ®Google Scholar
• Connor EE, Mwamuka J, Gole A, et al. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. SMALL 2005;1:325–7
   PubMed Web of Science ®Google Scholar
• Mei M, Ren Y, Zhou X, et al. Suppression of breast cancer cells in vitro by polyamidoamine-dendrimer-mediated 5-fluorouracil chemotherapy combined with antisense micro-RNA 21 gene therapy. J Appl Polym Sci 2009;114:3760–6
   Web of Science ®Google Scholar
• Banerjee D, Harfouche R, Sengupta S. Nanotechnology-mediated targeting of tumor angiogenesis. Vascular Cell 2011;3:3
   PubMedGoogle Scholar
• He YN, Zhang LH, Song CX. Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes. Int J Nanomed 2010;5:697–705
   PubMed Web of Science ®Google Scholar
• Kumar B, Yadav PR, Goel HC, Rizvi MMA. Recent developments in cancer therapy by the use of nanotechnology. Digest J Nanomater Biostruct 2009;4:51–7
   Web of Science ®Google Scholar
• Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257–72
   PubMed Web of Science ®Google Scholar
• Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750–63
   PubMed Web of Science ®Google Scholar
• Arruebo M, Valladares M, González-Fernández A. Antibody-conjugated nanoparticles for biomedical applications. J Nanomater 2009;2009:1–24
   Web of Science ®Google Scholar
• Zhou J, Leuschner C, Kumar C, et al. Sub-cellular accumulation of magnetic nanoparticles in breast tumors and metastases. Biomaterials 2006;27:2001–8
   PubMed Web of Science ®Google Scholar
• Aryal S, Hu CM, Zhang L. Combinatorial drug conjugation enables nanoparticle dual-drug delivery. SMALL 2010;6:1442–8
   PubMed Web of Science ®Google Scholar
• Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771–82
   PubMed Web of Science ®Google Scholar
• Stevanov M, Uskokovi D. Poly(lactide-co-glycolide)-based micro and nanoparticles for the controlled drug delivery of vitamins. Curr Nanosci 2009;5:1–14
   Web of Science ®Google Scholar
• Jack Hu CM, Zhang L. Therapeutic nanoparticles to combat cancer drug resistance. Curr Drug Metab 2009;10:836–41
   PubMed Web of Science ®Google Scholar
• Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 2000;85:217–29
   PubMed Web of Science ®Google Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2011;41:189–207
   Google Scholar
• Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin 2008;58:97–110
   PubMed Web of Science ®Google Scholar
• Jain A, Goel P, Shah S, et al. Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation. Biomed Pharmacother 2014;68:429–38
   PubMed Web of Science ®Google Scholar
• Yang T, Choi MK, Cui FD, et al. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 2007;120:169–77
   PubMed Web of Science ®Google Scholar
• Lorusso V, Manzione L, Silvestris N. Role of liposomal anthracyclines in breast cancer. Ann Oncol 2007;18:vi70–3
   PubMedGoogle Scholar
• Mirafzali Z. How many liposome based drugs are in the market? [Online]. Nashville: encapsula NanoSciences. 2011. Available from: http://www.liposomes.org/2011/03/how-many-liposome-based-drugs-have-been.html [last accessed 10 Dec 2012]
   Google Scholar
• Frechet JM. Dendrimers and supramolecular chemistry. Proc Natl Acad Sci USA 2002;99:4782–7
   PubMed Web of Science ®Google Scholar
• Wijagkanalan W, Kawakami S, Hashida M. Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations. Pharm Res 2011;28:1500–19
   PubMed Web of Science ®Google Scholar
• Rajesh Babu VM, Nikhat SR, Srikanth G. Dendrimers: a new carrier system for drug delivery. Int J Pharm Appl Sci 2010;1:1–10
   PubMedGoogle Scholar
• Cheng Y, Xu T. The effect of dendrimers on the pharmacodynamic and pharmacokinetic behaviors of non-covalently or covalently attached drugs. Eur J Med Chem 2008;43:2291–7
   PubMed Web of Science ®Google Scholar
• Khairnar GAC, Palve PR, Bhise SB, et al. Dendrimers: potential tool for enhancement of antifungal activity. Int J PharmTech Res 2010;2:736–9
   Google Scholar
• Mccarthy TD, Karellas P, Henderson SA, et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm 2005;2:312–18
   PubMed Web of Science ®Google Scholar
• Chen AM, Santhakumaran LM, Nair SK, et al. Oligodeoxynucleotide nanostructure formation in the presence of polypropyleneimine dendrimers and their uptake in breast cancer cells. Nanotechnology 2006;17:5449–60
   Web of Science ®Google Scholar
• Pan B, Cui D, Sheng Y, et al. Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res 2007;67:8156–63
   PubMed Web of Science ®Google Scholar
• Tang MF, Lei L, Guo SR, Huang WL. Recent progress in nanotechnology for cancer therapy. Chin J Cancer 2010;29:775–80
   PubMedGoogle Scholar
• Tan Pham JBJ, Halas NJ, Lee TR. Preparation and characterization of self assembled gold nanoparticles on amino functionalized SiO2 dielectric core. World Acad Sci Eng Technol 2010;64:353–6
   Google Scholar
• Loo C, Hirsch L, Lee MH, et al. Gold nanoshell bioconjugates for molecular imaging in living cell. Opt Lett 2005;30:1012–14
   PubMed Web of Science ®Google Scholar
• Loo C, Lin A, Hirsch L, et al. Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol Cancer Res Treat 2004;3:33–40
   PubMed Web of Science ®Google Scholar
• Weibo C, Ting G, Hao H, Jiangtao S. Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl 2008;2008:1–27
   Google Scholar
• Bardhan R, Lal S, Joshi A, Halas NJ. Theranostic nanoshells: from probe design to imaging and treatment of cancer. Acc Chem Res 2011;44:936–46
   PubMed Web of Science ®Google Scholar
• Wagner MK, Li F, Li JJ, et al. Use of quantum dots in the development of assays for cancer biomarkers. Anal Bioanal Chem 2010;397:3213–24
   PubMed Web of Science ®Google Scholar
• Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect 2006;114:165–72
   PubMed Web of Science ®Google Scholar
• Chan WC, Maxwell DJ, Gao X, et al. Luminescent quantum dots for multiplexed biological detection and imaging. Curr Opin Biotechnol 2002;13:40–6
   PubMed Web of Science ®Google Scholar
• Wang C, Gao X, Su X. In vitro and in vivo imaging with quantum dots. Anal Bioanal Chem 2010;397:1397–415
   PubMed Web of Science ®Google Scholar
• Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 2005;4:435–46
   PubMed Web of Science ®Google Scholar
• Ma Q, Lin Z, Yang N, Li Y, Su X. A novel carboxymethyl chitosan–quantum dot-based intracellular probe for Zn2+ ion sensing in prostate cancer cells. Acta Biomater 2014;10:868–74
   PubMed Web of Science ®Google Scholar
• Zhang H, Yee D, Wang C. Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives. Nanomedicine (London) 2008;3:83–91
   PubMed Web of Science ®Google Scholar
• Pathak S, Cao E, Davidson MC, et al. Quantum dot applications to neuroscience: new tools for probing neurons and glia. J Neurosci 2006;26:1893–5
   PubMed Web of Science ®Google Scholar
• Ben-Ari ET. Nanoscale quantum dots hold promise for cancer applications. J Natl Cancer Inst 2003;95:502–4
   PubMed Web of Science ®Google Scholar
• Reiss P, Protiere M, Li L. Core/Shell semiconductor nanocrystals. SMALL 2009;5:154–68
   PubMed Web of Science ®Google Scholar
• Hauck TS, Anderson RE, Fischer HC, et al. In vivo quantum-dot toxicity assessment. SMALL 2010;6:138–44
   PubMed Web of Science ®Google Scholar
• Adeli M, Hakimpoor F, Parsamanesh M, et al. Quantum dot-pseudopolyrotaxane supramolecules as anticancer drug delivery systems. Polymer 2011;52:2401–13
   Web of Science ®Google Scholar
• Ji SR, Liu C, Zhang B, et al. Carbon nanotubes in cancer diagnosis and therapy. Biochim Biophys Acta 2010;1806:29–35
   PubMed Web of Science ®Google Scholar
• Shao N, Lu S, Wickstrom E, Panchapakesan B. Integrated molecular targeting of IGF1R and HER2 surface receptors and destruction of breast cancer cells using single wall carbon nanotubes. Nanotechnology 2007;18:1–9
   Web of Science ®Google Scholar
• Teker K, Sirdeshmukh R, Panchapakesan B. Antibody functionalization of carbon nanotubes for breast cancer applications. Proc IEEE Sensors 2004;1–3:814–17
   Google Scholar
• Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005;26:3995–4021
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Othman SF, Curtis ET, et al. Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials 2011;32:1890–905
   PubMed Web of Science ®Google Scholar
• Douziech-Eyrolles L, Marchais H, Herve K, et al. Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles. Int J Nanomed 2007;2:541–50
   PubMed Web of Science ®Google Scholar
• Lu AH, Salabas EL, Schuth F. Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angew Chem Int Ed Engl 2007;46:1222–44
   PubMed Web of Science ®Google Scholar
• Sahoo B, Devi S, Dutta S, et al. Biocompatible mesoporous silica-coated superparamagnetic manganese ferrite nanoparticles for targeted drug delivery and MR imaging applications. J Colloid Interface Sci 2014;431:31–41
   PubMed Web of Science ®Google Scholar
• Tan MC (ed.). Superparamagnetic nanoparticles for biomedical applications. Trivandrum: Transworld Research Network; 2009
   Google Scholar
• HoráK D, Shagotova T, Mitina N, et al. Surface-initiated polymerization of 2-hydroxyethyl methacrylate from heterotelechelic oligoperoxide-coated γ-Fe2O3 nanoparticles and their engulfment by mammalian cells. Chem Mater 2011;23:2637–49
   Web of Science ®Google Scholar
• Lin MM, Kim HH, Kim H, et al. Surface activation and targeting strategies of superparamagnetic iron oxide nanoparticles in cancer-oriented diagnosis and therapy. Nanomedicine (London) 2010;5:109–33
   PubMed Web of Science ®Google Scholar
• Ye F, Qin J, Toprak M, Muhammed M. Multifunctional core–shell nanoparticles: superparamagnetic, mesoporous, and thermosensitive. J Nanoparticle Res 2011;13:6157–67
   Web of Science ®Google Scholar
• Mu B, Wang TM, Wu ZH, et al. Fabrication of functional block copolymer grafted superparamagnetic nanoparticles for targeted and controlled drug delivery. Colloids Surf A 2011;375:163–8
   Web of Science ®Google Scholar
• Mahmoudi M, Sant S, Wang B, et al. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev 2011;63:24–46
   PubMed Web of Science ®Google Scholar
• Finas D, Baumann K, Ruhland B, et al. Sentinel lymph node detection in breast cancer through superparamagnetic nanoparticles for magnetic particle imaging.(I: Nanopartikel (1)). Biomed Eng 2011;56:29–40
   Google Scholar
• Kohler N, Sun C, Wang J, Zhang MQ. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir 2005;21:8858–64
   PubMed Web of Science ®Google Scholar
• Yang H, Zhuang Y, Sun Y, et al. Targeted dual-contrast T1- and T2-weighted magnetic resonance imaging of tumors using multifunctional gadolinium-labeled superparamagnetic iron oxide nanoparticles. Biomaterials 2011;32:4584–93
   PubMed Web of Science ®Google Scholar
• Vivek R, Thangam R, Nipunbabu V, et al. Oxaliplatin-chitosan nanoparticles induced intrinsic apoptotic signaling pathway: a “smart” drug delivery system to breast cancer cell therapy. Int J Biol Macromol 2014;65:289–97
   PubMed Web of Science ®Google Scholar
• Fan L, Wu H, Zhang H, et al. Novel super pH-sensitive nanoparticles responsive to tumor extracellular pH. Carbohydr Polym 2008;73:390–400
   Web of Science ®Google Scholar
• Beloqui A, Coco R, Memvanga P, et al. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int J Pharm 2014;473:203–12
   PubMed Web of Science ®Google Scholar
• Liu R, Li D, He B, et al. Anti-tumor drug delivery of pH-sensitive poly(ethylene glycol)-poly(L-histidine-)-poly(L-lactide) nanoparticles. J Control Release 2011;152:49–56
   PubMed Web of Science ®Google Scholar
• Dua R, Zhang J, Nhonthachit P, et al. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat 2010;122:685–97
   PubMed Web of Science ®Google Scholar
• Liu P, Li Z, Zhu M, et al. Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma. J Mater Sci Mater Med 2010;21:551–6
   PubMed Web of Science ®Google Scholar
• Akhtar M, Ahamed M, Alhadlaq H, et al. Targeted anticancer therapy: overexpressed receptors and nanotechnology. Clin Chim Acta 2014;436:78–92
   PubMed Web of Science ®Google Scholar
• Leuschner C, Kumar CSSR, Hansel W, Hormes J. Targeting breast cancer cells and their metastases through luteinizing hormone releasing hormone (LHRH) receptors using magnetic nanoparticles. J Biomed Nanotechnol 2005;1:229–33
   Web of Science ®Google Scholar
• Bodek G, Rahman NA, Zaleska M, et al. A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CG beta conjugate. Breast Cancer Res Treat 2003;79:1–10
   PubMed Web of Science ®Google Scholar